Device Trial Radar · NCT07516457
Hydrogel Assessment for Local Treatment of Osteoarthritis
Last checked: Nov 20, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Apr 17, 2026
Primary completion
Oct 15, 2026
Study completion Jul 15, 2027
Sponsor
- Lead sponsor
- Allegro NV/SANot on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 8, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 35 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study aims to evaluate the safety and tolerability of one intra-articular injection of Hydrogel OA 2% for the symptomatic treatment of osteoarthritis of the knee.
Conditions
- Osteo Arthritis of the Knee
Interventions
Injection of Hydrogel OA 2%Device
Single injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of Device- or Procedure-Related Serious Adverse EventsTime frame: 13 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
AZ Sint Jan
Bruges, Belgium
AZ Monica
Deurne, Belgium
AZ Delta
Roeselare, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.